imetelstat shows promise in advanced myelofibrosis
Published 3 years ago • 1.5K plays • Length 4:39Download video MP4
Download video MP3
Similar videos
-
1:44
an update on imetelstat in r/r myelofibrosis
-
2:55
impactmf: imetelstat vs best available therapy in patients with myelofibrosis
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
1:40
the role of imetelstat in the treatment of myelofibrosis and insights into the impactmf study
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
56:56
transforming ecg & cardiac monitoring services at mayo clinic & beyond
-
13:05
finding hope in treatment: new developments in mpn research 2023
-
3:29
unmet needs and therapeutic strategies in essential thrombocythemia
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:59
phase iii trial of imetelstat versus best available therapy in refractory mf
-
7:42
phase ii trial of bomedemstat for advanced myelofibrosis
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
1:55
the promise of pelabresib in mf and insights into the manifest-2 study
-
0:50
recent updates from the promise study
-
4:48
an insight into the management of cytopenias in mf
-
1:19
the promise of precision medicine in mds
-
1:05
unmet needs in gvhd & the promise of regenerative medicine
-
2:43
the management of advanced phase mpns